Status:
COMPLETED
A Study To Evaluate The Safety And Efficacy Of Atorvastatin In Patients With Diabetes And High Cholesterol
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hyperlipidemias
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of atorvastatin for the treatment of Taiwanese patients with diabetes and high cholesterol.
Eligibility Criteria
Inclusion
- Adult Taiwanese outpatients with type 2 diabetes mellitus and high cholesterol
- Hemoglobin A1c levels of ≤10%, LDL-C levels of ≥130 mg/dL, and serum triglyceride levels of \<400 mg/dL
Exclusion
- Type I diabetes mellitus
- Secondary causes of high cholesterol
- Elevated liver enzymes
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2004
Estimated Enrollment :
155 Patients enrolled
Trial Details
Trial ID
NCT00645424
Start Date
December 1 2003
End Date
October 1 2004
Last Update
February 18 2021
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kaohsiung City, Taiwan
2
Pfizer Investigational Site
Kaohsiung Hsien, Taiwan
3
Pfizer Investigational Site
Taichung, Taiwan
4
Pfizer Investigational Site
Taipei, Taiwan